Fierce Biotech May 24, 2024
Analysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’ expectations for the bispecific antibody.
The slim slice of efficacy data, which Merus presented at the 2024 American Society of Clinical Oncology, comes from just 10 evaluable patients from a phase 2 trial. But the dual American and Dutch biotech has still been able to demonstrate a 60% response rate.
The study is assessing petosemtamab, a bispecific antibody for EGFR x LGR5 cancers, in combination with Keytruda as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma. By the Nov. 6, 2023, cutoff, 26 patients had been treated, with 24 continuing with their therapy.
Only 10 were evaluable for response at this point,...
Today's Sponsors
Today's Sponsor